GENZYME BUYS INTO CELTRIX' TGF-BETA-2 NEURODEGENERATIVE TREATMENT WITH $60 MIL.

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".